Professor Nicolas Voelcker named Australian Academy of Technology and Engineering Fellow
Professor Nicolas Voelcker from the Drug Delivery Disposition & Dynamics Theme at the Monash Institute of Pharmaceutical Sciences (MIPS) has been named an Australian Academy of Technology and Engineering Fellow.
23 October, 2019
A/Prof Joe Nicolazzo receives IMPACT grant from FIGHTMND
FightMND has announced a major funding commitment to advance research into Motor Neurone Disease as the fight to find effective treatments and a cure for the disease continues.
16 October, 2019
MIPS maintains top score in 2018 ERA rankings
The Monash Institute of Pharmaceutical Sciences has again received excellent results in the latest Excellence in Research for Australia (ERA) rankings.
17 September, 2019
PharmAlliance meets at Monash University
PharmAlliance, the research, professional practice and education partnership between the Schools of Pharmacy at Monash University, University College London (UCL) and the University of North Carolina at Chapel Hill (UNC), has held its
17 September, 2019Faculty success in major Commonwealth grant programs
The Monash Faculty of Pharmacy and Pharmaceutical Sciences has been awarded nearly $20 million dollars in research funding in the recent rounds of grants announced by the National Health and Medical Research Council (“NHMRC”) and the
20 December, 2017
MIPS partner, Starpharma, announces positive phase 1 clinical results for DEP® Docetaxel
11 October 2017
Scientists within Professor Chris Porter’s group at the ARC Centre of Excellence for Convergent Bio-Nano Science and Technology at the Monash Institute of Pharmaceutical
11 October, 2017
Monash scientists gain multimillion-dollar NIH grant for ‘superbug’ drug discovery program
August 2017
A world-leading team, led by Professor Jian Li from the Monash Biomedicine Discovery Institute (BDI), has been awarded a multi-million dollar grant
30 August, 2017
Monash University signs licensing deal for novel drug delivery technology
30 August 2017
The Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University today announced the licensing of a lymphatic drug targeting technology platform to clinical-stage biopharmaceutical
30 August, 2017